share_log

維亞生物：截至二零二四年六月三十日止六個月之中期業績公告

VIVA BIOTECH: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEX ·  Aug 29, 2024 18:08

Summary by Moomoo AI

維亞生物科技控股集團（「維亞生物」）公布截至2024年6月30日止六個月的中期業績。期內，集團收益由去年同期的人民幣1,142.2百萬元下降至981.8百萬元，毛利由406.0百萬元減至339.1百萬元，毛利率由35.5%降至34.5%。然而，淨利潤由去年同期的13.7百萬元大幅提升至144.2百萬元，主要得益於可轉債全額償還帶來的相關財務調整項的消除。經調整非國際財務報告準則淨利潤由去年同期的146.1百萬元增長至168.2百萬元。期內，維亞生物累計服務客戶數量增加至2,350家。報告期內，CRO業務收入下降12.5%，CDMO業務收入下降約15.0%，但公司通過降本增效等措施，將CRO的盈利水平維持在良好水平上。此外，公司在技術平台方面取得進展，引入人工智能技術，開發AI賦能SBDD一站式原創新藥物研發服務平台。截至報告期末，公司員工總人數為2,043人。
維亞生物科技控股集團（「維亞生物」）公布截至2024年6月30日止六個月的中期業績。期內，集團收益由去年同期的人民幣1,142.2百萬元下降至981.8百萬元，毛利由406.0百萬元減至339.1百萬元，毛利率由35.5%降至34.5%。然而，淨利潤由去年同期的13.7百萬元大幅提升至144.2百萬元，主要得益於可轉債全額償還帶來的相關財務調整項的消除。經調整非國際財務報告準則淨利潤由去年同期的146.1百萬元增長至168.2百萬元。期內，維亞生物累計服務客戶數量增加至2,350家。報告期內，CRO業務收入下降12.5%，CDMO業務收入下降約15.0%，但公司通過降本增效等措施，將CRO的盈利水平維持在良好水平上。此外，公司在技術平台方面取得進展，引入人工智能技術，開發AI賦能SBDD一站式原創新藥物研發服務平台。截至報告期末，公司員工總人數為2,043人。
Viva Biotech Holdings Group ("Viva Biotech") announced the interim performance for the six months ended June 30, 2024. During the period, the group's revenue decreased from RMB 1,142.2 million in the same period last year to RMB 981.8 million, gross profit decreased from RMB 406.0 million to RMB 339.1 million, and gross margin decreased from 35.5% to 34.5%. However, net profit increased significantly from RMB 13.7 million in the same period last year to RMB 144.2 million, mainly due to the elimination of related financial adjustments brought by the full redemption of convertible bonds. Adjusted net profit under international financial reporting standards increased from RMB 146.1 million in the same period last year to RMB 168.2 million. During the period, Viva Biotech's cumulative customer base increased to 2,350. During the reporting...Show More
Viva Biotech Holdings Group ("Viva Biotech") announced the interim performance for the six months ended June 30, 2024. During the period, the group's revenue decreased from RMB 1,142.2 million in the same period last year to RMB 981.8 million, gross profit decreased from RMB 406.0 million to RMB 339.1 million, and gross margin decreased from 35.5% to 34.5%. However, net profit increased significantly from RMB 13.7 million in the same period last year to RMB 144.2 million, mainly due to the elimination of related financial adjustments brought by the full redemption of convertible bonds. Adjusted net profit under international financial reporting standards increased from RMB 146.1 million in the same period last year to RMB 168.2 million. During the period, Viva Biotech's cumulative customer base increased to 2,350. During the reporting period, CRO business revenue decreased by 12.5%, and CDMO business revenue decreased by approximately 15.0%, but the company maintained the profitability level of CRO at a good level through measures such as cost reduction and efficiency improvement. In addition, the company made progress in the technology platform by introducing artificial intelligence technology and developing an AI-empowered SBDD one-stop original innovative drug research and development service platform. As of the end of the reporting period, the total number of company employees was 2,043.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    ZAI LAB
    09688
    -- 22.650
    CUTIA-B
    02487
    -- 5.410
    IMMUNEONCO-B
    01541
    -- 5.890
    TYK MEDICINES-B
    02410
    -- 23.050
    GIANT BIOGENE
    02367
    -- 60.800
    Log In for the Full List
    Discussing
    Trump 2.0 Era: How will global markets evolve?
    🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
    MicroStrategy Q4 2024 earnings conference call
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.